lockFact SheetCardiovascular disease – ORION-8 media summary
Long-term assessment of the efficacy and safety of inclisiran in patients with high risk of cardiovascular events
lockFact SheetCardiovascular disease – By the Numbers
Cardiovascular disease (CVD) is the leading cause of death worldwide. Investment in heart health has declined for decades.
lockFact SheetCardiovascular disease – VictORION media summary
A dynamic clinical trial program co-created with healthcare partners worldwide to generate evidence on the impact of cholesterol lowering with Leqvio® (Inclisiran).
lockFact Sheet52-week results for Cosentyx® in hidradenitis suppurativa: A summary
Discover the data published in The Lancet on the long-term effect of Cosentyx® (secukinumab) in adults with hidradenitis suppurativa from the SUNRISE and SUNSHINE trials.
lockDisease Awareness / Fact SheetSpinal Muscular Atrophy
Understanding spinal muscular atrophy, a rare, neuromuscular genetic disease.
lockScience & Innovation / Fact SheetThe Novartis AAV Platform
Modified viruses – including adeno-associated viruses – are an efficient way to transport therapeutic genetic material to affected cells.
lockScience & Innovation / Fact SheetThe Novartis Gene Therapies Manufacturing Process
Manufacturing of gene therapy is complex. Novartis has developed a reproducible manufacturing process.
lockCorporate Responsibility / Fact SheetAbout Novartis Gene Therapies
Novartis Gene Therapies is the world leader in gene therapy, and is reimagining medicine to transform the lives of patients.
lockScience & Innovation / Fact SheetAbout Gene Therapy
Gene therapy – an innovative approach to treating rare, genetic diseases.
lockProducts / Fact SheetRTH258 Brolucizumab Clinical Trials
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness.
lockProducts / Fact SheetKymriah® (tisagenlecleucel) in children and young adults with B-cell ALL that is refractory or relapsed at least twice
Kymriah® (pronounced: Kim-RYE-ah) is the first FDA-approved CAR-T cell therapy available in the US
lockProducts / Fact SheetThe JULIET Clinical Trial
The JULIET clinical trial is a global, multi-center Phase II registration trial investigating CTL019 (tisagenlecleucel) for use in diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma (NHL). The Novartis-sponsored JULIET trial was conducted in collaboration with the University of Pennsylvania to evaluate the safety and efficacy of CTL019 in adult patients with relapsed or refractory (r/r) DLBCL. Relapsed/refractory DLBCL is an aggressive (fast-growing), complex and difficult-to-treat disease, and patients with DLBCL often have worse prognosis than other forms of NHL.